NeuroVive appoints recognized scientific advisors and enters research agreements in NASH and hepatocellular carcinoma
Lund, Sweden, February 22, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced two new research agreements and the appointment of Professor Philippe Gallay, PhD, and Professor Massimo Pinzani, MD, PhD, FRCP, as scientific advisors. The aim of the agreements is to further explore NeuroVive’s new drug compounds in development for the treatment of NASH and hepatocellular carcinoma (HCC).In the new collaboration with Philippe Gallay, the research teams will explore the mechanisms of action of the potent anti-cancer